Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Pharming Group
ISIN NL0010391025
|WKN A1H65A
Market cap (in EUR)
972 m
Country
Netherlands
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands
Financials
Key metrics
| Market capitalisation, EUR | 972 m |
| EPS, EUR | -0.01 |
| P/B ratio | 4.3 |
| P/E ratio | 58.6 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 275 m |
| Net income, EUR | -11 m |
| Profit margin | -3.98% |
What ETF is Pharming Group in?
There are 2 ETFs which contain Pharming Group. All of these ETFs are listed in the table below. The ETF with the largest weighting of Pharming Group is the L&G Pharma Breakthrough UCITS ETF.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETF | 2.81% | Equity World Health Care Innovation | 16 |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist | 0.08% | Equity Europe Small Cap Climate Change | 332 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.